Becton Dickinson and Co (BDX.N)
232.32USD
1:29pm EDT
$2.83 (+1.23%)
$229.49
$230.21
$232.74
$229.53
80,220
413,428
$248.20
$177.67
About
Overall
| Beta: | 1.16 |
| Market Cap(Mil.): | $61,470.06 |
| Shares Outstanding(Mil.): | 266.24 |
| Dividend: | 0.75 |
| Yield (%): | 1.31 |
Financials
| BDX.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 92.05 | 35.24 | 32.21 |
| EPS (TTM): | 2.49 | -- | -- |
| ROI: | 1.92 | 14.18 | 13.05 |
| ROE: | 3.92 | 16.92 | 14.90 |
BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes
* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS
BRIEF-Becton, Dickinson To Divest Remaining Investment In Vyaire Medical
* BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS
BRIEF-Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe
* BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS
BRIEF-Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes
* BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING
BRIEF-Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay
* FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER Source text for Eikon: Further company coverage:
BRIEF-Becton Dickinson Q1 Loss Per Share $0.76
* BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD
BRIEF-BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit
* BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT
BRIEF-FDA Issues Warning Letter To Becton Dickinson & Co
* FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES
UPDATE 1-Becton Dickinson's $24 bln takeover of C R Bard set to close after China nod
* Becton had said China approval was last hurdle for deal to close
China commerce ministry conditionally approves Becton Dickinson-C R Bard merger
BEIJING China's commerce ministry said on Thursday that it has conditionally approved a merger between U.S. medical equipment supplier Becton Dickinson and its U.S. peer C R Bard .
Competitors
| Price | Chg | |
|---|---|---|
| Baxter International Inc (BAX.N) | $69.95 | +3.43 |
| Stryker Corporation (SYK.N) | $167.16 | +1.78 |
| Boston Scientific Corporation (BSX.N) | $29.39 | -0.04 |
| C R Bard Inc (BCR.N) | -- | -- |
| Hologic, Inc. (HOLX.OQ) | $39.02 | +0.17 |
| Quidel Corporation (QDEL.OQ) | $55.81 | +0.95 |
| Abbott Laboratories (ABT.N) | $59.14 | +0.49 |
| Gen-Probe Incorporated (GPRO.OQ) | $4.89 | +0.03 |
Estimates